Sartorius Stedim Biotech Stock
Stocks
DIM
FR0013154002
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
Real-time
Euronext Paris
13:42:54 11/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 186.70 EUR | +0.21% |
|
-1.89% | -11.10% |
| 09-08 | Sartorius Stedim Biotech : Barclays remains its Buy rating | ZD |
| 08-20 | UBS Upgrades Sartorius Stedim Biotech to Buy, Boosts PT | MT |
| Market Cap | 18.13B 21.08B 17.1B 15.58B 29.13B 2,015B 29.39B 204B 78.39B 1,022B 79.15B 77.42B 3,247B | P/E 2026 * |
47.5x | P/E 2027 * | 36.9x |
|---|---|---|---|---|---|
| Enterprise Value | 20.13B 23.41B 19B 17.31B 32.35B 2,238B 32.65B 226B 87.08B 1,135B 87.92B 86B 3,606B | EV / Sales 2026 * |
6.44x | EV / Sales 2027 * | 5.73x |
| Free-Float |
28.47% | Yield 2026 * |
0.45% | Yield 2027 * | 0.54% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| DIM | Real-time | |
CBOE
| DIMp | Real-time | |
|
CBOE
| 0NK7 | Real-time | |
|
Tradegate
| 56S1 | Real-time | |
|
OTC Markets
| SDMHF | Delayed | |
|
Deutsche Boerse AG
| 56S1 | Delayed | |
|
London S.E.
| 0NK7 | Delayed | |
|
Börse Stuttgart
| 56S1 | Delayed | |
|
Boerse Muenchen
| 56S1 | Real-time | |
|
Xetra
| 56S1 | Delayed | |
|
Borsa Italiana
| 4DIM | End-of-day quote | |
|
Wiener Boerse
| DIM | End-of-day quote |
Last Transcript : Sartorius Stedim Biotech
| 1 day | +0.21% | ||
| 1 week | -1.89% | ||
| Current month | -4.74% | ||
| 1 month | +3.49% | ||
| 3 months | +5.24% | ||
| 6 months | +13.56% | ||
| Current year | -11.10% |
| 1 week | 185 |  | 191.9 |
| 1 month | 178.3 | | 203 |
| Current year | 150 | | 224 |
| 1 year | 150 | | 224 |
| 3 years | 139.1 | | 281 |
| 5 years | 139.1 | | 548.2 |
| 10 years | 50.13 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 51 | 28/03/2023 |
| Chief Tech/Sci/R&D Officer | 61 | 08/09/2011 | |
Petra Müller
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 07/04/2015 | |
Susan Dexter
BRD | Director/Board Member | 69 | 07/04/2015 |
Lothar Kappich
BRD | Director/Board Member | 69 | 14/09/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/17/25 A | Sell | Company | 750,000 | 0.7706% | ||
| 2/16/24 A | Buy | Chief Executive Officer | 1,716,739 | 1.8624% | ||
| 3/2/22 A | Sell | Company | 200,442 | 0.2174% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.21% | -1.89% | +10.31% | -28.41% | 21.08B | |
| -1.78% | -4.99% | -20.10% | +2.61% | 179B | |
| -0.29% | -1.59% | -0.76% | +14.58% | 117B | |
| -0.73% | -4.82% | +8.31% | +80.61% | 61.25B | |
| -1.92% | -6.01% | +8.80% | +41.11% | 50.24B | |
| -1.88% | -5.97% | -6.37% | -33.87% | 48.05B | |
| +0.75% | -5.80% | +11.20% | -19.01% | 31.89B | |
| -4.88% | -11.48% | - | - | 28.42B | |
| +2.17% | +0.44% | +34.88% | -12.44% | 24.23B | |
| +0.49% | -7.65% | -12.44% | +4.86% | 21.4B | |
| Average | -0.52% | -5.28% | +3.76% | +5.56% | 58.26B | |
| Weighted average by Cap. | -0.29% | -4.31% | -3.40% | +11.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.13B 3.64B 2.95B 2.69B 5.02B 348B 5.07B 35.14B 13.52B 176B 13.65B 13.35B 560B | 3.47B 4.03B 3.27B 2.98B 5.57B 386B 5.62B 38.98B 15B 196B 15.15B 14.81B 621B |
| Net income | 381M 443M 360M 328M 613M 42.4B 618M 4.29B 1.65B 21.51B 1.67B 1.63B 68.31B | 483M 562M 456M 415M 776M 53.71B 783M 5.43B 2.09B 27.24B 2.11B 2.06B 86.53B |
| Net Debt | 2.01B 2.34B 1.89B 1.73B 3.23B 223B 3.26B 22.57B 8.68B 113B 8.77B 8.58B 360B | 1.76B 2.04B 1.66B 1.51B 2.82B 195B 2.85B 19.73B 7.59B 98.99B 7.67B 7.5B 314B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | €186.70 | +0.21% | 4,023 |
| 10/09/26 | €186.30 | -2.26% | 63,463 |
| 09/09/26 | €190.60 | +0.11% | 79,481 |
| 08/09/26 | €190.40 | +2.09% | 53,269 |
| 07/09/26 | €186.50 | -2.00% | 42,207 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
